Number 894 • September 2020

Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Cyclogyl 1% Ophthalmic Solution (DIN 00252506) manufactured by Alcon Canada Inc., Cyclopentolate HCl 1% Ophthalmic Solution (Minims) (DIN 02148382) manufactured by Bausch and Lomb Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alcon Canada Inc. has advised Alberta Blue Cross that the shortage Cyclogyl 1% Ophthalmic Solution (DIN 00252506) has been resolved. These products were removed from the Critical Supply Product List **September 3, 2020**.

As a result, Cyclopentolate HCl 1% Ophthalmic Solution (Minims) (DIN 02148382) will no longer be considered a temporary benefit for the *ADBL* after **October 2, 2020**.

Due to the shortages of the following products, Losartan 50 mg Tablet (DIN 02388871) manufactured by Sanis Health Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description	Manufacturer	
02353504	Apo-Losartan 50 mg Tablet	Apotex Inc.	
02403331	Auro-Losartan 50 mg Tablet	Auro Pharma Inc.	
02445972	Bio-Losartan 50 mg Tablet	Biomed Pharma	
02398842	Jamp-Losartan 50 mg Tablet	Jamp Pharma Corporation	
02388804	Losartan 50 mg Tablet	Sivem Pharmaceuticals ULC	
02405741	Mint-Losartan 50 mg Tablet	Mint Pharmaceuticals Inc.	
02309769	pms-Losartan 50 mg Tablet	Pharmascience Inc.	
02313340	Sandoz Losartan 50 mg Tablet	Sandoz Canada Inc.	
02424975	Septa-Losartan 50 mg Tablet	Septa Pharmaceuticals Inc	
02357968	Teva-Losartan 50 mg Tablet	Teva Canada Limited	
02182874	Cozaar 50 mg Tablet	Merck Canada Inc.	

Sivem Pharmaceuticals ULC, Sandoz Canada Inc., Teva Canada Limited, and Merck Canada Inc. have advised Alberta Blue Cross that the shortages of Losartan 50 mg Tablet (DIN 02388804), Sandoz Losartan 50 mg Tablet (DIN 02313340), Teva-Losartan 50 mg Tablet (DIN 02357968) and Cozaar 50 mg Tablet (DIN 02182874) respectively have been resolved. These products were removed from the Critical Supply Product List **September 9, 2020**.

As a result, Losartan 50 mg Tablet (DIN 02388871) will no longer be considered a temporary benefit for the ADBL after October 9, 2020.

Due to the shortage of Ultravate 0.05% Topical Cream (DIN 01962701) manufactured by Bausch Health, Ultravate 0.05% Topical Ointment (DIN 01962728) manufactured by Bausch Health was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Bausch Health has advised Alberta Blue Cross that the shortage for Ultravate 0.05% Topical Cream (DIN 01962701) has been resolved. These products were removed from the Critical Supply Product List **September 9, 2020**.

As a result, Ultravate 0.05% Topical Ointment (DIN 01962728) will no longer be considered a temporary benefit for the *ADBL* **after October 9, 2020**.

Due to the shortages of the following products, Auro-Valsartan 40 mg Tablet (DIN 02414201) manufactured by Auro Pharma Inc., Ran-Valsartan 40 mg Tablet (DIN 02363062) manufactured by Ranbaxy Pharmaceuticals Canada Inc, Teva-Valsartan 40 mg Tablet (DIN 02356643) manufactured by Teva Canada Limited and Diovan 40 mg Tablet (DIN 02270528) manufactured by Novartis Pharmaceuticals Canada Inc. were added as temporary benefits for the Alberta Drug Benefit List (ADBL).

DIN	Product Description	Manufacturer	
02414228	Auro-Valsartan 80 mg Tablet	Auro Pharma Inc.	
02403331	Ran-Valsartan 80 mg Tablet	Ranbaxy Pharmaceuticals Canada Inc	
02445972	Sandoz Valsartan 80 mg Tablet	Sandoz Canada Inc.	
02398842	Teva-Valsartan 80 mg Tablet	Teva Canada Limited	
02244781	Diovan 80 mg Tablet	Novartis Pharmaceuticals Canada Inc.	

Sandoz Canada Inc. and Novartis Pharmaceuticals Canada Inc. have advised Alberta Blue Cross that the shortages of Sandoz Valsartan 80 mg Tablet (DIN 02445972) and Diovan 80 mg Tablet (DIN 02244781) respectively have been resolved. These products were removed from the Critical Supply Product List September 9, 2020.

As a result, Auro-Valsartan 40 mg Tablet (DIN 02414201), Ran-Valsartan 40 mg Tablet (DIN 02363062), Teva-Valsartan 40 mg Tablet (DIN 02356643) and Diovan 40 mg Tablet (DIN 02270528) will no longer be considered temporary benefits for the ADBL after October 9, 2020.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. and Mylan Pharmaceuticals ULC that the shortages for Apo-Cilazapril 5 mg Tablet (DIN 02291150) and Mylan-Cilazapril 5 mg Tablet (DIN 02283794) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective October 5, 2020. The following grouping was removed from the Critical Supply Product List September 3, 2020.

CILAZAPRIL

5 MG TABLET

00002291150	APO-CILAZAPRIL	APX	\$ 0.4989
00002283794	MYLAN-CILAZAPRIL	MYP	\$ 0.4989
00001911481	INHIBACE	CAG	\$ 0.9978

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



